Physician profile
Halie L Ory
NPI 1972974400
$7,500.87
in general payments reported to CMS, 2019-2025
23 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,114 · 2022: $1,124 · 2023: $1,294 · 2024: $1,803 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,238 · Education: $24.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,238.39 |
| Education | $24.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,520.21 | 2021-2025 | Caplyta |
| Abbvie INC. | $861.68 | 2021-2025 | |
| Alkermes, INC. | $850.76 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $816.69 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Supernus Pharmaceuticals, INC. | $604.97 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $413.93 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $390.96 | 2022-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $378.64 | 2021-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $299.05 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $294.85 | 2021-2025 | Ingrezza |
| Corium, LLC | $288.82 | 2023-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $248.87 | 2021-2022 | |
| Indivior INC. | $132.22 | 2022-2023 | Sublocade, Perseris |
| Janssen Pharmaceuticals, INC | $96.52 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $66.36 | 2022-2023 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $53.57 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $53.00 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $44.62 | 2024 | Cobenfy |
| Lundbeck LLC | $22.74 | 2023 | Rexulti |
| Owp Pharmaceuticals, INC. | $18.24 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.41 | 2023 | Quviviq |
| Sage Therapeutics, LLC | $13.38 | 2024 | |
| Adlon Therapeutics L.P. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halie Ory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.